CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma

[1]  P. L. Bergsagel,et al.  Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial , 2018, Leukemia.

[2]  P. Moreau,et al.  Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions , 2017, British journal of haematology.

[3]  A. Im,et al.  Immunotherapy in hematologic malignancies: past, present, and future , 2017, Journal of Hematology & Oncology.

[4]  G. Zalcman,et al.  First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers , 2017, British Journal of Cancer.

[5]  Shaji K. Kumar,et al.  Immune Therapies in Multiple Myeloma , 2016, Clinical Cancer Research.

[6]  M. Dimopoulos,et al.  Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. , 2016, The Lancet. Haematology.

[7]  H. Goldschmidt,et al.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[8]  Michael L. Wang,et al.  Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. , 2016, Blood.

[9]  C. Morimoto,et al.  A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition , 2016, Cancer Cell International.

[10]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[11]  A. Palumbo,et al.  Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. , 2016, Blood.

[12]  A. Palumbo,et al.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. , 2015, The New England journal of medicine.

[13]  Jessica Katz,et al.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.

[14]  J. Laubach,et al.  CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon , 2015, Clinical Cancer Research.

[15]  Yongdong Feng,et al.  Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions , 2015, International journal of cancer.

[16]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[17]  C. Morimoto,et al.  Blockade of CD26 Signaling Inhibits Human Osteoclast Development , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  G. Stefanzl,et al.  Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. , 2014, Blood.

[19]  S. Iwata,et al.  CD9 Negatively Regulates CD26 Expression and Inhibits CD26-Mediated Enhancement of Invasive Potential of Malignant Mesothelioma Cells , 2014, PloS one.

[20]  S. Iwata,et al.  CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion , 2013, BMC Cancer.

[21]  H. Goldschmidt,et al.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[22]  Kohji Yamada,et al.  Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription , 2013, PloS one.

[23]  Michael A. Sellitto,et al.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. , 2012, Blood.

[24]  S. Singhal,et al.  A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. , 2012, Blood.

[25]  S. Jagannath,et al.  Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Jakubowiak,et al.  Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Y. Takeshima,et al.  CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma , 2012, Clinical Cancer Research.

[28]  A. Jakubowiak,et al.  Monoclonal antibodies in the treatment of multiple myeloma , 2011, British journal of haematology.

[29]  I. Endo,et al.  The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells , 2011, Leukemia.

[30]  Kenneth C. Anderson,et al.  Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors , 2011, The Journal of Immunology.

[31]  T. Yau,et al.  A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. , 2010, Cell stem cell.

[32]  S. Molica,et al.  CD26 expression in mature B‐cell neoplasia: its possible role as a new prognostic marker in B‐CLL , 2009, Hematological oncology.

[33]  B. Barlogie,et al.  Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease , 2009, British journal of haematology.

[34]  S. Hirohashi,et al.  Distinct gene expression-defined classes of gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Pienta,et al.  CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12 , 2008, Clinical & Experimental Metastasis.

[36]  F. Zhan,et al.  CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008, Clinical Cancer Research.

[37]  S. Rajkumar,et al.  Anti‐CD20 monoclonal antibody therapy in multiple myeloma , 2008, British journal of haematology.

[38]  F. Zhan,et al.  Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts , 2008, Leukemia.

[39]  C. Morimoto,et al.  Humanized Anti-CD26 Monoclonal Antibody as a Treatment for Malignant Mesothelioma Tumors , 2007, Clinical Cancer Research.

[40]  S. Iwata,et al.  Anti-CD26 Monoclonal Antibody–Mediated G1-S Arrest of Human Renal Clear Cell Carcinoma Caki-2 Is Associated with Retinoblastoma Substrate Dephosphorylation, Cyclin-Dependent Kinase 2 Reduction, p27kip1 Enhancement, and Disruption of Binding to the Extracellular Matrix , 2006, Clinical Cancer Research.

[41]  F. Zhan,et al.  Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival , 2006, British journal of haematology.

[42]  C. Morimoto,et al.  CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. , 2005, Cancer research.

[43]  K. Yata,et al.  The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells , 2004, Leukemia.

[44]  B. Barlogie,et al.  Cancer and the Microenvironment , 2004, Cancer Research.

[45]  Kazuya Sato,et al.  T‐large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition , 2003, British journal of haematology.

[46]  D. Maloney,et al.  Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. , 2002, Blood.

[47]  G. Mills,et al.  In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  J. Epstein,et al.  The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. , 1999, Blood.

[49]  B. Barlogie,et al.  Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations , 1998 .

[50]  S. Monfardini,et al.  The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. , 1995, Blood.

[51]  B. Fleischer,et al.  CD26: a surface protease involved in T-cell activation. , 1994, Immunology today.

[52]  R. Ueda,et al.  Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. , 1993, Blood.

[53]  B. Seed,et al.  Cloning and functional expression of the T cell activation antigen CD26. , 1992, Journal of immunology.

[54]  J. McCune,et al.  Implantation and maintenance of functional human bone marrow in SCID-hu mice , 1992 .

[55]  C. Morimoto,et al.  Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. , 1992, Molecular immunology.

[56]  C. Morimoto,et al.  1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. , 1991, Journal of immunology.

[57]  N. Letvin,et al.  1F7, a novel cell surface molecule, involved in helper function of CD4 cells. , 1989, Journal of immunology.

[58]  J. Holloman.  A new horizon. , 1966, Journal of the National Medical Association.

[59]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[60]  A. Palumbo,et al.  Multiple myeloma. , 2011, The New England journal of medicine.

[61]  C. Morimoto,et al.  Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. , 2008, Frontiers in bioscience : a journal and virtual library.

[62]  C. Morimoto,et al.  The role of CD26/dipeptidyl peptidase IV in cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[63]  稲元 輝生.  Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27[kip1] enhancement, and disruption of binding to the extracellular matrix , 2007 .

[64]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[65]  B. Barlogie,et al.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. , 1998, Blood.

[66]  M. Hegen,et al.  Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function. , 1998, Molecular immunology.

[67]  J. McCune,et al.  Implantation and maintenance of functional human bone marrow in SCID-hu mice. , 1992, Blood.

[68]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.